277 related articles for article (PubMed ID: 21203958)
21. Solution NMR Studies of Mycobacterium tuberculosis Proteins for Antibiotic Target Discovery.
Kim DH; Kang SM; Lee BJ
Molecules; 2017 Aug; 22(9):. PubMed ID: 28858250
[TBL] [Abstract][Full Text] [Related]
22. Identification of new benzamide inhibitor against α-subunit of tryptophan synthase from Mycobacterium tuberculosis through structure-based virtual screening, anti-tuberculosis activity and molecular dynamics simulations.
Naz S; Farooq U; Ali S; Sarwar R; Khan S; Abagyan R
J Biomol Struct Dyn; 2019 Mar; 37(4):1043-1053. PubMed ID: 29502488
[TBL] [Abstract][Full Text] [Related]
23. Structural analyses of the MazEF4 toxin-antitoxin pair in
Ahn DH; Lee KY; Lee SJ; Park SJ; Yoon HJ; Kim SJ; Lee BJ
J Biol Chem; 2017 Nov; 292(46):18832-18847. PubMed ID: 28972145
[TBL] [Abstract][Full Text] [Related]
24. High-throughput screen identifies small molecule inhibitors targeting acetyltransferase activity of Mycobacterium tuberculosis GlmU.
Rani C; Mehra R; Sharma R; Chib R; Wazir P; Nargotra A; Khan IA
Tuberculosis (Edinb); 2015 Dec; 95(6):664-677. PubMed ID: 26318557
[TBL] [Abstract][Full Text] [Related]
25. Targeting type VII/ESX secretion systems for development of novel antimycobacterial drugs.
Bottai D; Serafini A; Cascioferro A; Brosch R; Manganelli R
Curr Pharm Des; 2014; 20(27):4346-56. PubMed ID: 24245757
[TBL] [Abstract][Full Text] [Related]
26. Recent advancements in the development of anti-tuberculosis drugs.
Chetty S; Ramesh M; Singh-Pillay A; Soliman ME
Bioorg Med Chem Lett; 2017 Feb; 27(3):370-386. PubMed ID: 28017531
[TBL] [Abstract][Full Text] [Related]
27. Phenotypic and genomic comparison of Mycobacterium aurum and surrogate model species to Mycobacterium tuberculosis: implications for drug discovery.
Namouchi A; Cimino M; Favre-Rochex S; Charles P; Gicquel B
BMC Genomics; 2017 Jul; 18(1):530. PubMed ID: 28705154
[TBL] [Abstract][Full Text] [Related]
28. Structural genomics approach to drug discovery for Mycobacterium tuberculosis.
Ioerger TR; Sacchettini JC
Curr Opin Microbiol; 2009 Jun; 12(3):318-25. PubMed ID: 19481971
[TBL] [Abstract][Full Text] [Related]
29. Opportunities for Overcoming
Torfs E; Piller T; Cos P; Cappoen D
Int J Mol Sci; 2019 Jun; 20(12):. PubMed ID: 31212777
[TBL] [Abstract][Full Text] [Related]
30. Structural biology and biochemistry of cytochrome P450 systems in Mycobacterium tuberculosis.
McLean KJ; Munro AW
Drug Metab Rev; 2008; 40(3):427-46. PubMed ID: 18642141
[TBL] [Abstract][Full Text] [Related]
31. Advances in Mycobacterium tuberculosis structural genomics: investigating potential chinks in the armor of a deadly pathogen.
Chim N; McMath LM; Beeby M; Goulding CW
Infect Disord Drug Targets; 2009 Nov; 9(5):475-92. PubMed ID: 19594421
[TBL] [Abstract][Full Text] [Related]
32. Drug discovery in tuberculosis. New drug targets and antimycobacterial agents.
Campaniço A; Moreira R; Lopes F
Eur J Med Chem; 2018 Apr; 150():525-545. PubMed ID: 29549838
[TBL] [Abstract][Full Text] [Related]
33. [Recent progress in mycobacteriology].
Okada M; Kobayashi K
Kekkaku; 2007 Oct; 82(10):783-99. PubMed ID: 18018602
[TBL] [Abstract][Full Text] [Related]
34. Crystal structure of Mycobacterium tuberculosis ketol-acid reductoisomerase at 1.0 Å resolution - a potential target for anti-tuberculosis drug discovery.
Lv Y; Kandale A; Wun SJ; McGeary RP; Williams SJ; Kobe B; Sieber V; Schembri MA; Schenk G; Guddat LW
FEBS J; 2016 Apr; 283(7):1184-96. PubMed ID: 26876563
[TBL] [Abstract][Full Text] [Related]
35. The TB structural genomics consortium: a resource for Mycobacterium tuberculosis biology.
Terwilliger TC; Park MS; Waldo GS; Berendzen J; Hung LW; Kim CY; Smith CV; Sacchettini JC; Bellinzoni M; Bossi R; De Rossi E; Mattevi A; Milano A; Riccardi G; Rizzi M; Roberts MM; Coker AR; Fossati G; Mascagni P; Coates AR; Wood SP; Goulding CW; Apostol MI; Anderson DH; Gill HS; Eisenberg DS; Taneja B; Mande S; Pohl E; Lamzin V; Tucker P; Wilmanns M; Colovos C; Meyer-Klaucke W; Munro AW; McLean KJ; Marshall KR; Leys D; Yang JK; Yoon HJ; Lee BI; Lee MG; Kwak JE; Han BW; Lee JY; Baek SH; Suh SW; Komen MM; Arcus VL; Baker EN; Lott JS; Jacobs W; Alber T; Rupp B
Tuberculosis (Edinb); 2003; 83(4):223-49. PubMed ID: 12906835
[TBL] [Abstract][Full Text] [Related]
36. Modeling the structural origins of drug resistance to isoniazid via key mutations in Mycobacterium tuberculosis catalase-peroxidase, KatG.
Marney MW; Metzger RP; Hecht D; Valafar F
Tuberculosis (Edinb); 2018 Jan; 108():155-162. PubMed ID: 29523317
[TBL] [Abstract][Full Text] [Related]
37. Identification of TB-E12 as a novel FtsZ inhibitor with anti-tuberculosis activity.
Lin Y; Zhang H; Zhu N; Wang X; Han Y; Chen M; Jiang J; Si S
Tuberculosis (Edinb); 2018 May; 110():79-85. PubMed ID: 29779778
[TBL] [Abstract][Full Text] [Related]
38. New approaches to tuberculosis--novel drugs based on drug targets related to toll-like receptors in macrophages.
Tomioka H
Curr Pharm Des; 2014; 20(27):4404-17. PubMed ID: 24245765
[TBL] [Abstract][Full Text] [Related]
39. A novel inhibitor of indole-3-glycerol phosphate synthase with activity against multidrug-resistant Mycobacterium tuberculosis.
Shen H; Wang F; Zhang Y; Huang Q; Xu S; Hu H; Yue J; Wang H
FEBS J; 2009 Jan; 276(1):144-54. PubMed ID: 19032598
[TBL] [Abstract][Full Text] [Related]
40. A whole genome bioinformatic approach to determine potential latent phase specific targets in Mycobacterium tuberculosis.
Defelipe LA; Do Porto DF; Pereira Ramos PI; Nicolás MF; Sosa E; Radusky L; Lanzarotti E; Turjanski AG; Marti MA
Tuberculosis (Edinb); 2016 Mar; 97():181-92. PubMed ID: 26791267
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
